Pancreatic Cancer Research

Clinical trialPhase 1Unknown

GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results

A Multicenter, Open-label Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of GH21 Capsules in Subjects With Advanced Solid Tumors

Outcome
Outcome unknown
Phase
Phase 1
Status
Unknown
Study type
Interventional
Start
20 February 2022
Listed end
20 February 2025
Enrollment
68 participants
Sites
9
Primary outcomes
Determination of Maximum Tolerated Dose (MTD) of GH21.; Characterize the Safety of GH21
Sponsor type
Academic / other
Results posted
No
Last update
16 July 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.